A detailed history of Dunhill Financial, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Dunhill Financial, LLC holds 102 shares of BIIB stock, worth $16,188. This represents 0.01% of its overall portfolio holdings.

Number of Shares
102
Previous 87 17.24%
Holding current value
$16,188
Previous $20.1 Million 1.32%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$189.07 - $236.8 $2,836 - $3,552
15 Added 17.24%
102 $19.8 Million
Q2 2024

Aug 09, 2024

BUY
$190.52 - $236.72 $14,479 - $17,990
76 Added 690.91%
87 $20.1 Million
Q1 2024

May 13, 2024

SELL
$212.02 - $267.71 $2,544 - $3,212
-12 Reduced 52.17%
11 $2.31 Million
Q4 2023

Feb 12, 2024

BUY
$222.59 - $267.94 $5,119 - $6,162
23 New
23 $5.94 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.9B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Dunhill Financial, LLC Portfolio

Follow Dunhill Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dunhill Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dunhill Financial, LLC with notifications on news.